Cargando…
Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB
Placebo-controlled, randomized, phase 2b trial was conducted in 34 adults comprising 18 first-diagnosed (52.9%), 6 relapsed (17.6%), and 10 MDR-TB (29.4%) cases to investigate the safety and efficacy of an oral immune adjunct (V5). The immunotherapy (N = 24) and placebo (N = 10) arms received once-d...
Autores principales: | Butov, Dmitry A, Pashkov, Yuri N, Stepanenko, Anna L, Choporova, Aleksandra I, Butova, Tanya S, Batdelger, Dendev, Jirathitikal, Vichai, Bourinbaiar, Aldar S, Zaitzeva, Svetlana I |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031205/ https://www.ncbi.nlm.nih.gov/pubmed/21244690 http://dx.doi.org/10.1186/1476-8518-9-3 |
Ejemplares similares
-
Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study
por: Bourinbaiar, Aldar S, et al.
Publicado: (2010) -
Serodeconversion of HIV Antibody-Positive AIDS Patients Following Treatment with V-1 Immunitor
por: Metadilogkul, Orapun, et al.
Publicado: (2009) -
Pilot trial of oral therapeutic HIV vaccine, V-1 Immunitor, on HIV and HIV/HCV patients in Russia
por: Bourinbaiar, Aldar, et al.
Publicado: (2010) -
Phase III, placebo-controlled, randomized, double-blind trial of tableted, therapeutic TB vaccine (V7) containing heat-killed M. vaccae administered daily for one month
por: Bourinbaiar, Aldar S., et al.
Publicado: (2019) -
Immunotherapy of liver cancer with hepcortespenlisimut-L: open-label Phase II clinical study in patients with advanced HCC
por: Tarakanovskaya, Marina G, et al.
Publicado: (2015)